Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

1.2K
β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in...
1.2K
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

842
Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is...
842
Antihypertensive Drugs: Types of β-Blockers01:28

Antihypertensive Drugs: Types of β-Blockers

1.1K
β receptors are classified into three subclasses: β1, β2, and β3. β1 receptors are primarily located in the heart and kidneys. When they get activated, they increase heart rate, contractility, and renin release. This process enhances blood pressure and aids in stress management. In contrast, β2 receptors are situated mainly in the lungs, blood vessels, and skeletal muscles. Upon activation, they trigger smooth muscle relaxation, causing bronchodilation and...
1.1K
Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers01:25

Adrenergic Antagonists: Chemistry and Classification of β-Receptor Blockers

959
β-adrenergic antagonists, or β-blockers, modulate the sympathetic nervous system by targeting β-adrenoceptors and inhibiting catecholamine-mediated sympathetic responses. β-blockers differ in their adrenoceptor subtype affinity, lipophilicity, and α-blocking capabilities. The history of β-blocker development began with the prototype, dichloroisoprenaline, which exhibited partial agonist activity. As a result, propranolol was developed as a pure antagonist but...
959
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

538
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
538
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers01:24

Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers

1.1K
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which...
1.1K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Allergic Contact Dermatitis With Erythema Multiforme-Like Features Induced by Isoconazole Nitrate.

Contact dermatitis·2026
Same author

Ochre Fluorescence in Melanoma Under Ultraviolet-Induced Fluorescence Dermoscopy: A Case Series.

International journal of dermatology·2026
Same author

Improvement of geographic tongue with adalimumab in a patient with psoriatic arthritis.

Italian journal of dermatology and venereology·2026
Same author

Dermoscopic Interface Features in Melanoma-Seborrheic Keratosis Collision Tumors: A Scoping Review with an Illustrative Case Report on Wood's Lamp Dermoscopy.

Diagnostics (Basel, Switzerland)·2026
Same author

Clinical and Photobiological Response to Omalizumab in Refractory Solar Urticaria.

International journal of dermatology·2026
Same author

Morbihan disease in an Asian patient: diagnostic and therapeutic challenges.

Dermatology reports·2026
Same journal

Increased Risk of Cutaneous T-Cell Lymphoma Development after Dupilumab Use for Atopic Dermatitis.

Dermatologic therapy·2024
Same journal

Correction to "Adjuvant PD-1 inhibitor versus high-dose interferon α-2b for Chinese patients with cutaneous and acral melanoma: A retrospective cohort analysis".

Dermatologic therapy·2022
Same journal

A case of erythema nodosum concomitant with ulcerative colitis relieved by tofacitinib.

Dermatologic therapy·2022
Same journal

A case report of vitiligo following toripalimab therapy for a patient with metastatic melanoma.

Dermatologic therapy·2022
Same journal

High versus low dose oral isotretinoin in the treatment of cutaneous and genital warts.

Dermatologic therapy·2022
Same journal

Evaluation of the efficacy and relapse rates of treatment protocols for moderate acne using isotretinoin based on the global acne grading system: Randomized, controlled, comparative study.

Dermatologic therapy·2022
See all related articles

Related Experiment Video

Updated: Nov 3, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K

Topical beta-blockers in dermatologic therapy.

Angela Filoni1,2, Francesca Ambrogio1, Aurora De Marco1

  • 1Section of Dermatology, Department of Biomedical Science and Human Oncology, University of Bari, Bari, Italy.

Dermatologic Therapy
|June 2, 2021
PubMed
Summary
This summary is machine-generated.

Topical beta-blockers are increasingly used in dermatology for various skin conditions beyond infantile hemangiomas. These treatments are proving safe and effective for conditions like pyogenic granuloma and Kaposi sarcoma, with minimal side effects.

Keywords:
Kaposibeta-blockershemangiomas/vascular tumorsparonychiatherapy-topicalwounds

More Related Videos

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

3.0K
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.2K

Related Experiment Videos

Last Updated: Nov 3, 2025

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis
11:39

The Goeckerman Regimen for the Treatment of Moderate to Severe Psoriasis

Published on: July 11, 2013

39.2K
Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging
11:07

Visualizing and Quantifying Pharmaceutical Compounds within Skin using Coherent Raman Scattering Imaging

Published on: November 24, 2021

3.0K
Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid
04:12

Author Spotlight: Non-Surgical Treatment of Melasma– Microneedling with Tranexamic Acid

Published on: January 19, 2024

1.2K

Area of Science:

  • Dermatology
  • Pharmacology

Background:

  • Beta-blockers are increasingly utilized in dermatological treatments.
  • Their use for conditions other than infantile hemangiomas is often off-label.

Purpose of the Study:

  • To review the emerging applications of topical beta-blockers in dermatology.
  • To assess their efficacy and safety in treating various cutaneous diseases.

Main Methods:

  • Literature review of studies on topical beta-blocker use in dermatology.
  • Analysis of data regarding treatment of infantile hemangioma, pyogenic granuloma, Kaposi sarcoma, wounds, and nail paronychia.

Main Results:

  • Topical beta-blockers demonstrate safety and efficacy across multiple dermatological conditions.
  • Adverse effects are predominantly localized to the application site.

Conclusions:

  • Topical beta-blockers represent a safe and effective therapeutic option for numerous skin diseases.
  • Further research, including randomized trials, is needed to solidify their role in dermatological practice.